article
Recognition of phosphohistidine-containing peptides by antibodies
In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
List view / Grid view
Monoclonal Antibody
news
“Woman-controlled, on-demand” contraceptive product developed in US
US researchers have developed an antisperm monoclonal antibody that could become a safe and effective birth control method.
article
Better therapeutic antibodies by design
The binding specificity and high binding affinity of therapeutic antibodies makes them an ideal therapy for treating a wide range of human disorders. Advancements in antibody technologies have resulted in huge development success along with a boost in novel and improved treatment strategies. However, specific challenges and considerations are faced…
article
How to mix the best anti-SARS-CoV-2 cocktail
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
news
Antibody cocktail shown to neutralise SARS-CoV-2 variants of concern
A new antibody cocktail made from three mAbs neutralised several SARS-CoV-2 variants in pre-clinical studies.
news
Researchers identify antibodies with potent effects against malaria
Six antibodies specific to the circumsporozoite protein of the malaria parasite have shown promise as therapeutic interventions, a study has shown.
news
Experimental mAb subdues type 1 diabetes in laboratory mice
A monoclonal antibody given to mice reversed type 1 diabetes by suppressing the actions of glucagon, a study has shown.
article
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
news
Novel antibody candidate could offer pan-coronavirus protection
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
news
Antibody effector functions are key to combatting COVID-19, finds study
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
news
Anti-C5aR antibody shows promise as immuno-oncology treatment
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
news
Screening process may enhance mAb drug development, say scientists
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
news
Protective antibodies identified for rare polio-like disease in children
Researchers isolated monoclonal antibodies from children who has survived infection by EV-D68, the virus linked to acute flaccid myelitis (AFM). These antibodies protected mice against infection.
article
Antibodies against viral disease: highlighting technologies behind COVID-19 antibody therapy
Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and treat cases of severe disease. Armed with the capacity to neutralise pathogens and orchestrate the immune system, promising antibody candidates for multiple viral indications, including HIV, continue to emerge. Technology…